Ad Scientiam launches international study to assess disability progression in multiple sclerosis with MSCopilot®

On September 12, 2023, Ad Scientiam, a global leader in digital biomarkers, announced the launch of MS-DETECT, an international, multicenter longitudinal study, in partnership with Sanofi.

MS-DETECT aims to evaluate the ability of MSCopilot®, a software medical device, to detect early signs of worsening disability in people with multiple sclerosis (MS).

The study builds on Ad Scientiam's expertise in MS and will enroll 314 patients in the United States, Canada, Germany, Italy, Spain, Denmark and France.